Project detailsProject start:2013Pathology:Cancer in ChildrenNeuroblastomaUniversity:Universiteit Gent (UGent)
To discriminate (ultra) high risk Neuroblastoma patients
Neuroblastoma is a sympathetic nervous system cancer in young children, an orphan disease.
Management of neuroblastoma patients is tailored to the risk stratification of individual patients.
The signatures are used to discriminate low/intermediate risk from high-risk patients and identify ultra high-risk patients that do not benefit from current high-risk treatment protocols
Scientific project description
Prof. Vandesompele & Speleman have teamed up to develop one integrated diagnostic test for prognosis / outcome prediction in children with neuroblastoma.
Tumor-specific m/miRNA signatures (as developed by Jo Vandesompele, project started in 2008) are invasive and not all neuroblastoma patients need a biopsy. For this reason, this follow-on project aims to develop a new non-invasive serum test based on mi-RNA.
As a second step the team will try to combine the DNA methylation (project F Speleman started in 2009) and m/miRNA signatures (project J Vandesompele) into a single m/miRNA-DNA methylation integrated signature, both on the primary tumor and serum level.
- Confirmation of a tumor specific 59-messenger RNA (mRNA) classifier (published in Lancet Oncology, 2009)
- Confirmation of a tumor-specific micro RNA (miRNA) classifier in archived and fresh samples (published in Clinical Cancer Research, 2011)
- IP has been secured on 59-mRNA signature and a 25-miRNA signatures
- 6 publications
- Serum miRNA and (tissue) methylation signatures are currently being confirmed
- Co-funding secured from the National Lottery
Cancer in Children, Neuroblastoma
Follow-on valorization project